The ontogeny of TRH and of a proposed TRH metabolite, histidyl proline diketopiperazine (His-Pro DKP), was determined in the rat central nervous system and pancreas as a means of studying the interrelationship of these peptides. Various regions of the rat brain, spinal cord, and pancreas were dissected from animals ranging in age from prenatal day 17 to adult. The tissues were extracted for TRH and His-Pro DKP, and tissue levels of the two peptides were measured by specific RIAs. We found increasing TRH levels in the hypothalamus, spinal cord, and multiple extrahypothalamic brain regions in the developing rat [e.g. from 21 +/- 3 (+/- SE) pg/hypothalamus on prenatal day 17 to 2606 +/- 296 pg/hypothalamus in the adult]. In the rat pancreas, however, TRH levels initially increased from 354 +/- 37 pg/pancreas on prenatal day 21 to 749 +/- 68 pg/pancreas on postnatal day 7, but from day 7 to adulthood, the TRH content fell dramatically, being undetectable in the adult rat pancreas. The His-Pro DKP content increased in nearly all tissues studied, with peak values occurring on postnatal days 10 and 28 and in the adult. There was little apparent correlation, however, between the anatomical distribution and ontogeny of TRH compared with those of His-Pro DKP. We conclude that His-Pro DKP and TRH have widespread distributions involving the hypothalamus, extrahypothalamic brain, spinal cord, and pancreas in the developing rat. TRH and His-Pro DKP, however, have differing patterns of ontogeny in the rat, suggesting that His-Pro DKP may be derived from sources other than just TRH.
We have measured plasma von Willebrand factor (VWF) as the factor VIII-related antigen, plasma fibronectin, and two of the serum somatomedins, insulin-like growth factor I (IGF I) and IGF II, in 51 diabetic patients and 25 nondiabetic control subjects. VWF was significantly higher in the diabetic group than in the controls (173 +/- 9% SEM versus 101 +/- 9%, P less than 0.001), as has been reported by others. However, within the diabetic group there was no significant difference in VWF between those patients without retinopathy, those with background or proliferative retinopathy, or those with macular edema. There was also no difference in VWF between the diabetic subjects with and those without proteinuria. These results rule against a previously advanced hypothesis that the increase in VWF in patients with diabetes is secondary to microangiopathy. No significant difference was observed in fibronectin, IGF I, or IGF II between the diabetic and control groups, between the diabetic group without retinopathy and the retinopathic subgroups, and between the diabetic subjects with and without proteinuria. In the diabetic patients, there was no correlation between diabetic control as assessed by glycosylated hemoglobin and glycosylated serum protein, and the plasma levels of VWF, fibronectin, IGF I, or IGF II. The results of this study strongly suggest that neither plasma VWF, fibronectin, IGF I, nor IGF II plays an important primary role in the pathogenesis of diabetic microvascular disease, although one or more of these factors might play a permissive role.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.